HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFkappaB.

Abstract
We describe a highly efficient use of lentiviral validation-based insertional mutagenesis (VBIM) to generate large populations of mammalian cells in which a strong promoter is inserted into many different genomic loci, causing greatly increased expression of downstream sequences. Many different selections or screens can follow, to isolate dominant mutant clones with a desired phenotypic change. The inserted promoter can be excised or silenced at will, to prove that the insertion caused the mutation. Cloning DNA flanking the insertion site identifies the locus precisely. VBIM virus particles are pseudotyped with VSV G protein, allowing efficient infection of most mammalian cell types, including non-dividing cells, and features are included that give high yields of stable virus stocks. In several different selections, useful mutants have been obtained at frequencies of approximately 10(-6) or higher. We used the VBIM technique to isolate mutant human cells in which the F-box leucine-rich protein 11 (FBXL11), a histone H3K36 demethylase, is shown to be a negative regulator of NFkappaB. High levels of FBXL11 block the ability of NFkappaB to bind to DNA or activate gene expression, and siRNA-mediated reduction of FBXL11 expression has the opposite effects. The H212A mutation of FBXL11 abolishes both its histone H3K36 demethylase activity and its ability to inhibit NFkappaB. Thus, we have used a powerful tool for mutagenesis of mammalian cells to reveal an aspect of the complex regulation of NFkappaB-dependent signaling.
AuthorsTao Lu, Mark W Jackson, Aatur D Singhi, Eugene S Kandel, Maojing Yang, Yi Zhang, Andrei V Gudkov, George R Stark
JournalProceedings of the National Academy of Sciences of the United States of America (Proc Natl Acad Sci U S A) Vol. 106 Issue 38 Pg. 16339-44 (Sep 22 2009) ISSN: 1091-6490 [Electronic] United States
PMID19805303 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Validation Study)
Chemical References
  • Antibiotics, Antineoplastic
  • F-Box Proteins
  • Histones
  • NF-kappa B
  • RNA, Small Interfering
  • Recombinant Fusion Proteins
  • Bleomycin
  • Green Fluorescent Proteins
  • Zeocin
  • Jumonji Domain-Containing Histone Demethylases
  • KDM2A protein, human
  • Oxidoreductases, N-Demethylating
  • Lysine
Topics
  • Antibiotics, Antineoplastic (pharmacology)
  • Bleomycin (pharmacology)
  • Blotting, Northern
  • Blotting, Western
  • Cell Line
  • Cell Survival (drug effects)
  • F-Box Proteins (genetics, metabolism)
  • Genetic Vectors (genetics)
  • Green Fluorescent Proteins (genetics, metabolism)
  • HT29 Cells
  • Histones (metabolism)
  • Humans
  • Jumonji Domain-Containing Histone Demethylases
  • Lysine (metabolism)
  • Methylation
  • Microscopy, Fluorescence
  • Mutagenesis, Insertional (methods)
  • Mutation
  • NF-kappa B (genetics, metabolism)
  • Oxidoreductases, N-Demethylating (genetics, metabolism)
  • RNA, Small Interfering (genetics)
  • Recombinant Fusion Proteins (genetics, metabolism)
  • Reverse Transcriptase Polymerase Chain Reaction
  • Transfection

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: